A ribonucleoprotein octamer for targeted siRNA delivery

Hurdles in cell-specific delivery of small interfering RNA (siRNA) in vivo hinder the clinical translation of RNA interference (RNAi). A fundamental problem concerns conflicting requirements for the design of the delivery vehicles: cationic materials facilitate cargo condensation and endosomolysis,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature biomedical engineering 2018-05, Vol.2 (5), p.326-337
Hauptverfasser: Tai, Wanyi, Li, Junwei, Corey, Eva, Gao, Xiaohu
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 337
container_issue 5
container_start_page 326
container_title Nature biomedical engineering
container_volume 2
creator Tai, Wanyi
Li, Junwei
Corey, Eva
Gao, Xiaohu
description Hurdles in cell-specific delivery of small interfering RNA (siRNA) in vivo hinder the clinical translation of RNA interference (RNAi). A fundamental problem concerns conflicting requirements for the design of the delivery vehicles: cationic materials facilitate cargo condensation and endosomolysis, yet hinder in vivo targeting and colloidal stability. Here, we describe a self-assembled, compact (~30 nm) and biocompatible ribonucleoprotein-octamer nanoparticle that achieves endosomal destabilization and targeted delivery. The protein octamer consists of a poly(ethylene glycol) scaffold, a sterically masked endosomolytic peptide and a double-stranded RNA-binding domain, providing a discrete number of siRNA loading sites and a high siRNA payload (>30 wt%), and offering flexibility in both siRNA and targeting-ligand selection. We show that a ribonucleoprotein octamer against the polo-like kinase 1 gene and bearing a ligand that binds to prostate-specific membrane antigen leads to efficient gene silencing in prostate tumour cells in vitro and when intravenously injected in mouse models of prostate cancer. The octamer's versatile nanocarrier design should offer opportunities for the clinical translation of therapies based on intracellularly acting biologics.
doi_str_mv 10.1038/s41551-018-0214-1
format Article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6136846</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>30936447</sourcerecordid><originalsourceid>FETCH-LOGICAL-p163t-3055b8786df9462de23ee36257ada9c9c8a73c1a0b0af72d83638397a0b70f0c3</originalsourceid><addsrcrecordid>eNpVkNtKAzEYhIMgttQ-gDeyLxBN9s_xRihFrVAURMG7JZv8WyPbzZLdFvr2FjygVwMzzAczhFxwdsUZmOtBcCk5ZdxQVnJB-QmZllxqaoR6m5D5MHwwxrgFYbU8IxNgFpQQekr0osixTt3Ot5j6nEaMXZH86LaYiyblYnR5gyOGYojPj4siYBv3mA_n5LRx7YDzb52R17vbl-WKrp_uH5aLNe25gpECk7I22qjQWKHKgCUggiqldsFZb71xGjx3rGau0WUwoMCA1UdDs4Z5mJGbL26_q7cYPHZjdm3V57h1-VAlF6v_SRffq03aV4qDOq4_Ai7_An6bPxfAJ9PQXhw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A ribonucleoprotein octamer for targeted siRNA delivery</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Tai, Wanyi ; Li, Junwei ; Corey, Eva ; Gao, Xiaohu</creator><creatorcontrib>Tai, Wanyi ; Li, Junwei ; Corey, Eva ; Gao, Xiaohu</creatorcontrib><description>Hurdles in cell-specific delivery of small interfering RNA (siRNA) in vivo hinder the clinical translation of RNA interference (RNAi). A fundamental problem concerns conflicting requirements for the design of the delivery vehicles: cationic materials facilitate cargo condensation and endosomolysis, yet hinder in vivo targeting and colloidal stability. Here, we describe a self-assembled, compact (~30 nm) and biocompatible ribonucleoprotein-octamer nanoparticle that achieves endosomal destabilization and targeted delivery. The protein octamer consists of a poly(ethylene glycol) scaffold, a sterically masked endosomolytic peptide and a double-stranded RNA-binding domain, providing a discrete number of siRNA loading sites and a high siRNA payload (&gt;30 wt%), and offering flexibility in both siRNA and targeting-ligand selection. We show that a ribonucleoprotein octamer against the polo-like kinase 1 gene and bearing a ligand that binds to prostate-specific membrane antigen leads to efficient gene silencing in prostate tumour cells in vitro and when intravenously injected in mouse models of prostate cancer. The octamer's versatile nanocarrier design should offer opportunities for the clinical translation of therapies based on intracellularly acting biologics.</description><identifier>EISSN: 2157-846X</identifier><identifier>DOI: 10.1038/s41551-018-0214-1</identifier><identifier>PMID: 30936447</identifier><language>eng</language><publisher>England</publisher><subject>Antineoplastic Agents - chemistry ; Antineoplastic Agents - pharmacokinetics ; Cell Line, Tumor ; Drug Delivery Systems - methods ; Gene Silencing ; Humans ; Polyethylene Glycols - chemistry ; Ribonucleoproteins - chemistry ; Ribonucleoproteins - pharmacokinetics ; RNA, Small Interfering - chemistry ; RNA, Small Interfering - genetics ; RNA, Small Interfering - pharmacokinetics</subject><ispartof>Nature biomedical engineering, 2018-05, Vol.2 (5), p.326-337</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-6054-0530</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30936447$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tai, Wanyi</creatorcontrib><creatorcontrib>Li, Junwei</creatorcontrib><creatorcontrib>Corey, Eva</creatorcontrib><creatorcontrib>Gao, Xiaohu</creatorcontrib><title>A ribonucleoprotein octamer for targeted siRNA delivery</title><title>Nature biomedical engineering</title><addtitle>Nat Biomed Eng</addtitle><description>Hurdles in cell-specific delivery of small interfering RNA (siRNA) in vivo hinder the clinical translation of RNA interference (RNAi). A fundamental problem concerns conflicting requirements for the design of the delivery vehicles: cationic materials facilitate cargo condensation and endosomolysis, yet hinder in vivo targeting and colloidal stability. Here, we describe a self-assembled, compact (~30 nm) and biocompatible ribonucleoprotein-octamer nanoparticle that achieves endosomal destabilization and targeted delivery. The protein octamer consists of a poly(ethylene glycol) scaffold, a sterically masked endosomolytic peptide and a double-stranded RNA-binding domain, providing a discrete number of siRNA loading sites and a high siRNA payload (&gt;30 wt%), and offering flexibility in both siRNA and targeting-ligand selection. We show that a ribonucleoprotein octamer against the polo-like kinase 1 gene and bearing a ligand that binds to prostate-specific membrane antigen leads to efficient gene silencing in prostate tumour cells in vitro and when intravenously injected in mouse models of prostate cancer. The octamer's versatile nanocarrier design should offer opportunities for the clinical translation of therapies based on intracellularly acting biologics.</description><subject>Antineoplastic Agents - chemistry</subject><subject>Antineoplastic Agents - pharmacokinetics</subject><subject>Cell Line, Tumor</subject><subject>Drug Delivery Systems - methods</subject><subject>Gene Silencing</subject><subject>Humans</subject><subject>Polyethylene Glycols - chemistry</subject><subject>Ribonucleoproteins - chemistry</subject><subject>Ribonucleoproteins - pharmacokinetics</subject><subject>RNA, Small Interfering - chemistry</subject><subject>RNA, Small Interfering - genetics</subject><subject>RNA, Small Interfering - pharmacokinetics</subject><issn>2157-846X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkNtKAzEYhIMgttQ-gDeyLxBN9s_xRihFrVAURMG7JZv8WyPbzZLdFvr2FjygVwMzzAczhFxwdsUZmOtBcCk5ZdxQVnJB-QmZllxqaoR6m5D5MHwwxrgFYbU8IxNgFpQQekr0osixTt3Ot5j6nEaMXZH86LaYiyblYnR5gyOGYojPj4siYBv3mA_n5LRx7YDzb52R17vbl-WKrp_uH5aLNe25gpECk7I22qjQWKHKgCUggiqldsFZb71xGjx3rGau0WUwoMCA1UdDs4Z5mJGbL26_q7cYPHZjdm3V57h1-VAlF6v_SRffq03aV4qDOq4_Ai7_An6bPxfAJ9PQXhw</recordid><startdate>20180501</startdate><enddate>20180501</enddate><creator>Tai, Wanyi</creator><creator>Li, Junwei</creator><creator>Corey, Eva</creator><creator>Gao, Xiaohu</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6054-0530</orcidid></search><sort><creationdate>20180501</creationdate><title>A ribonucleoprotein octamer for targeted siRNA delivery</title><author>Tai, Wanyi ; Li, Junwei ; Corey, Eva ; Gao, Xiaohu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p163t-3055b8786df9462de23ee36257ada9c9c8a73c1a0b0af72d83638397a0b70f0c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Antineoplastic Agents - chemistry</topic><topic>Antineoplastic Agents - pharmacokinetics</topic><topic>Cell Line, Tumor</topic><topic>Drug Delivery Systems - methods</topic><topic>Gene Silencing</topic><topic>Humans</topic><topic>Polyethylene Glycols - chemistry</topic><topic>Ribonucleoproteins - chemistry</topic><topic>Ribonucleoproteins - pharmacokinetics</topic><topic>RNA, Small Interfering - chemistry</topic><topic>RNA, Small Interfering - genetics</topic><topic>RNA, Small Interfering - pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tai, Wanyi</creatorcontrib><creatorcontrib>Li, Junwei</creatorcontrib><creatorcontrib>Corey, Eva</creatorcontrib><creatorcontrib>Gao, Xiaohu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Nature biomedical engineering</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tai, Wanyi</au><au>Li, Junwei</au><au>Corey, Eva</au><au>Gao, Xiaohu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A ribonucleoprotein octamer for targeted siRNA delivery</atitle><jtitle>Nature biomedical engineering</jtitle><addtitle>Nat Biomed Eng</addtitle><date>2018-05-01</date><risdate>2018</risdate><volume>2</volume><issue>5</issue><spage>326</spage><epage>337</epage><pages>326-337</pages><eissn>2157-846X</eissn><abstract>Hurdles in cell-specific delivery of small interfering RNA (siRNA) in vivo hinder the clinical translation of RNA interference (RNAi). A fundamental problem concerns conflicting requirements for the design of the delivery vehicles: cationic materials facilitate cargo condensation and endosomolysis, yet hinder in vivo targeting and colloidal stability. Here, we describe a self-assembled, compact (~30 nm) and biocompatible ribonucleoprotein-octamer nanoparticle that achieves endosomal destabilization and targeted delivery. The protein octamer consists of a poly(ethylene glycol) scaffold, a sterically masked endosomolytic peptide and a double-stranded RNA-binding domain, providing a discrete number of siRNA loading sites and a high siRNA payload (&gt;30 wt%), and offering flexibility in both siRNA and targeting-ligand selection. We show that a ribonucleoprotein octamer against the polo-like kinase 1 gene and bearing a ligand that binds to prostate-specific membrane antigen leads to efficient gene silencing in prostate tumour cells in vitro and when intravenously injected in mouse models of prostate cancer. The octamer's versatile nanocarrier design should offer opportunities for the clinical translation of therapies based on intracellularly acting biologics.</abstract><cop>England</cop><pmid>30936447</pmid><doi>10.1038/s41551-018-0214-1</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-6054-0530</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier EISSN: 2157-846X
ispartof Nature biomedical engineering, 2018-05, Vol.2 (5), p.326-337
issn 2157-846X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6136846
source MEDLINE; SpringerLink Journals
subjects Antineoplastic Agents - chemistry
Antineoplastic Agents - pharmacokinetics
Cell Line, Tumor
Drug Delivery Systems - methods
Gene Silencing
Humans
Polyethylene Glycols - chemistry
Ribonucleoproteins - chemistry
Ribonucleoproteins - pharmacokinetics
RNA, Small Interfering - chemistry
RNA, Small Interfering - genetics
RNA, Small Interfering - pharmacokinetics
title A ribonucleoprotein octamer for targeted siRNA delivery
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T10%3A16%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20ribonucleoprotein%20octamer%20for%20targeted%20siRNA%20delivery&rft.jtitle=Nature%20biomedical%20engineering&rft.au=Tai,%20Wanyi&rft.date=2018-05-01&rft.volume=2&rft.issue=5&rft.spage=326&rft.epage=337&rft.pages=326-337&rft.eissn=2157-846X&rft_id=info:doi/10.1038/s41551-018-0214-1&rft_dat=%3Cpubmed%3E30936447%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/30936447&rfr_iscdi=true